CEACAM5 and neoplasm: In the last 5-year period (2007–2011, n = 88; 53.0%), the indications were broader and included patients with high tumor load (3 or more metastases or large metastasis above 30 mm (diameter) or synchronous metastases) and from January 2010 young patients with elevated CEA and ECOG performance status 0-1 [24].